Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: MarketLine (a Datamonitor Company)
$175.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Astellas Pharma Inc and Medivation, Inc. Announce XTANDI® (Enzalutamide) Capsules Receiving Health Canada Approval for Treatment of Metastatic Castration-Resistant Prostate Cancer


Monday, 3 Jun 2013 08:00pm EDT 

Astellas Pharma Inc. and Medivation, Inc. on June 4, 2013 announced that after a priority review, Health Canada has approved XTANDI® (enzalutamide) capsules for the treatment of patients with metastatic castration-resistant prostate cancer in the setting of medical or surgical castration who have received docetaxel therapy. 

Company Quote

1399.0
-12.5 -0.89%
1:47am EDT